GenVec, Inc. (Nasdaq:GNVC) announced that it will release financial results for the second quarter ended June 30, 2008 on Thursday, August 7, 2008 after market close. GenVec will hold a conference call at 10:00 a.m. EDT on Friday, August 8, 2008 to discuss the company’s second quarter results.

To listen to the live conference call, please dial 888-679-8035 (U.S. or Canada) or 617-213-4848 (international) and use access code 49766522. Participants may pre-register for the call anytime at: www.theconferencingservice.com/prereg/key.process?key=P3CV7UAXC. Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 12:00 p.m. on August 8, 2008 through August 15, 2008. To listen to the audio replay, dial 888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access code 94750325.

A live webcast of the conference call will be available on the Company’s website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on “Investor Relations,” and click on “Webcasts and Data.”

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product candidate, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer and is being evaluated in additional clinical trials in other tumor types. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company’s various filings with the Securities and Exchange Commission.

GenVec, Inc.
Douglas J. Swirsky
Chief Financial Officer
240-632-5510
dswirsky@genvec.com